221 related articles for article (PubMed ID: 38041083)
1. Efficacy of transarterial chemoembolization with drug-eluting beads combined with systemic chemotherapy and targeted therapy in colorectal cancer liver metastasis.
Chen YC; Huang CW; Li CC; Chang TK; Su WC; Chen PJ; Yeh YS; Chang YT; Tsai HL; Shih MP; Wang JY
World J Surg Oncol; 2023 Dec; 21(1):378. PubMed ID: 38041083
[TBL] [Abstract][Full Text] [Related]
2. Drug-eluting beads transcatheter arterial chemoembolization combined with systemic therapy versus systemic therapy alone as first-line treatment for unresectable colorectal liver metastases.
Wang F; Chen L; Bin C; Cao Y; Wang J; Zhou G; Zheng C
Front Oncol; 2024; 14():1338293. PubMed ID: 38720801
[TBL] [Abstract][Full Text] [Related]
3. Drug-eluting bead transarterial chemoembolization (DEB-TACE) versus conventional transarterial chemoembolization (cTACE) in colorectal liver metastasis: Efficacy, safety, and prognostic factors.
Zhang H; Wu C; Chen M; Sun Y; Han J
J Cancer Res Ther; 2023 Dec; 19(6):1525-1532. PubMed ID: 38156918
[TBL] [Abstract][Full Text] [Related]
4. Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
Tang J; Huang Z; Xu J; Lv Q; Wang P
Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101814. PubMed ID: 34597848
[TBL] [Abstract][Full Text] [Related]
5. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
Zhang ZS; Li HZ; Ma C; Xiao YD
BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814
[TBL] [Abstract][Full Text] [Related]
6. Callispheres® drug-eluting beads transarterial chemoembolization might be an efficient and safety down-staging therapy in unresectable liver cancer patients.
Peng N; Mao L; Tao Y; Xiao K; Yuan G; He S
World J Surg Oncol; 2022 Aug; 20(1):254. PubMed ID: 35941634
[TBL] [Abstract][Full Text] [Related]
7. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.
Shi Q; Liu J; Li T; Zhou C; Wang Y; Huang S; Yang C; Chen Y; Xiong B
Clin Res Hepatol Gastroenterol; 2022 May; 46(5):101893. PubMed ID: 35247625
[TBL] [Abstract][Full Text] [Related]
8. The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy.
Wang M; Sun L; Han X; Ren J; Li H; Wang W; Xu W; Liang C; Duan X
Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102060. PubMed ID: 36473631
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of doxorubicin-eluting CalliSpheres® beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma.
Bi Y; Shi X; Ren J; Yi M; Han X; Song M
BMC Gastroenterol; 2021 May; 21(1):231. PubMed ID: 34020608
[TBL] [Abstract][Full Text] [Related]
10. The second-line treatment of hepatocellular carcinoma with CalliSpheres drug-eluting bead transarterial chemoembolization combined with regorafenib: A safety and efficacy analysis.
Liu S; Liu C; Wang Q; Liu Y; Wang D; Zhao G; Yu G
Ir J Med Sci; 2024 Jun; 193(3):1215-1222. PubMed ID: 38300460
[TBL] [Abstract][Full Text] [Related]
11. Preliminary outcomes of raltitrexed eluting bead-transarterial chemoembolization using Callispheres® beads for gastrointestinal adenocarcinoma liver metastasis.
Bi Y; Jiao D; Wang Y; Han X; Ren J
World J Surg Oncol; 2022 Jul; 20(1):229. PubMed ID: 35821043
[TBL] [Abstract][Full Text] [Related]
12. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
[No Abstract] [Full Text] [Related]
13. Drug-Eluting Bead Transarterial Chemoembolization Versus Radiofrequency Ablation as an Initial Treatment of Single Small (≤ 3 cm) Hepatocellular Carcinoma.
Lee S; Jeong YY; Lee BC; Shin SS; Heo SH; Kim HO; Park C; Jeong WG
J Korean Med Sci; 2023 Oct; 38(42):e362. PubMed ID: 37904659
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Drug-Eluting Bead Transarterial Chemoembolization in the Treatment of Colorectal Cancer Liver Metastasis.
Chen S; Yang Y; Jiao Y; Hou L; Chang H; Liu S; Yan Z
J Healthc Eng; 2022; 2022():4930047. PubMed ID: 35463654
[TBL] [Abstract][Full Text] [Related]
15. Safety, efficacy, and survival of drug-eluting beads-transarterial chemoembolization vs. conventional-transarterial chemoembolization in advanced HCC patients with main portal vein tumor thrombus.
Chen J; Lai L; Zhou C; Luo J; Wang H; Li M; Huang M
Cancer Imaging; 2023 Jul; 23(1):70. PubMed ID: 37481660
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) plus apatinib versus DEB-TACE alone in treating huge hepatocellular carcinoma patients.
Li N; Chen J
Ir J Med Sci; 2022 Dec; 191(6):2611-2617. PubMed ID: 35083645
[TBL] [Abstract][Full Text] [Related]
17. Transarterial chemoembolization with raltitrexed-based or floxuridine-based chemotherapy for unresectable colorectal cancer liver metastasis.
Wei N; Zhang B; Wang Y; He XH; Xu LC; Li GD; Wang YH; Wang GZ; Huang HZ; Li WT
Clin Transl Oncol; 2019 Apr; 21(4):443-450. PubMed ID: 30306400
[TBL] [Abstract][Full Text] [Related]
18. Treatment efficacy and safety of regorafenib plus drug-eluting beads-transarterial chemoembolization versus regorafenib monotherapy in colorectal cancer liver metastasis patients who fail standard treatment regimens.
Cao F; Zheng J; Luo J; Zhang Z; Shao G
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2993-3002. PubMed ID: 34302208
[TBL] [Abstract][Full Text] [Related]
19. Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma.
Huang J; Huang W; Zhan M; Guo Y; Liang L; Cai M; Lin L; He M; Lian H; Lu L; Zhu K
J Hepatocell Carcinoma; 2021; 8():1445-1458. PubMed ID: 34858889
[TBL] [Abstract][Full Text] [Related]
20. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
